Evidence map›Paper›PMID 41044072›Full record

ArticleScientific reports2025

Prevalence and impact of thyroid dysfunction in patients with rheumatoid arthritis.

Safa Rahmouni, Malek Dhifallah, Mehdi Mrad, Eya Bouallègue, Khaoula Zouaoui, Asma Krir, Sonia Rekik, Hiba Wahabi, Soumaya Boussaid, Hela Sahli and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Safa RahmouniRheumatology Department, La Rabta Hospital, Tunis, Tunisia.ORCID http://orcid.org/0000-0001-7955-8653
Malek DhifallahRheumatology Department, La Rabta Hospital, Tunis, Tunisia. dhifallahmalek13@gmail.com.ORCID http://orcid.org/0000-0002-8023-7096
Mehdi MradLaboratory of Biochemistry and Hormonology, Institut Pasteur de Tunis, Tunis, Tunisia.ORCID http://orcid.org/0000-0001-8483-9927
Eya BouallègueLaboratory of Biochemistry and Hormonology, Institut Pasteur de Tunis, Tunis, Tunisia.ORCID http://orcid.org/0009-0000-3680-9918
Khaoula ZouaouiRheumatology Department, La Rabta Hospital, Tunis, Tunisia.ORCID http://orcid.org/0000-0003-0048-2428
Asma KrirLaboratory of Biochemistry and Hormonology, Institut Pasteur de Tunis, Tunis, Tunisia.
Sonia RekikRheumatology Department, La Rabta Hospital, Tunis, Tunisia.ORCID http://orcid.org/0000-0002-8524-6223
Hiba WahabiRheumatology Department, La Rabta Hospital, Tunis, Tunisia.
Soumaya BoussaidRheumatology Department, La Rabta Hospital, Tunis, Tunisia.ORCID http://orcid.org/0000-0002-9185-1710
Hela SahliRheumatology Department, La Rabta Hospital, Tunis, Tunisia.ORCID http://orcid.org/0000-0001-8383-2707
Afef BahlousLaboratory of Biochemistry and Hormonology, Institut Pasteur de Tunis, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid disorders are common in patients with autoimmune diseases such as rheumatoid arthritis (RA). Both conditions present significant public health concerns due to their impact on quality of life and increased mortality. The aim of this study was to assess the prevalence of thyroid abnormalities in and investigate their influence on rheumatoid arthritis characteristics. This was a case-control study involving adult female patients with RA and age-matched healthy controls. RA disease activity was evaluated using the Disease Activity Score (DAS28), and functional impact was assessed using the Health Assessment Questionnaire (HAQ). Serum thyroid function tests were performed, including thyroid-stimulating hormone (TSH), free thyroxine (FT4), and antithyroid antibodies (TAAs), including anti-thyroglobulin antibodies (TgAb), anti-thyroperoxidase antibodies (TPOAb), and TSH receptor antibodies (TRAb). The study included 58 female RA patients, with a mean age of 52 ± 14.2 years. The median disease duration was 10.41 years. The median DAS28-CRP was 4.03, and the median HAQ was 1.34. The median FT4 and TSH levels were 15.01 [13.48;16.71] and 1.42 [0.91;2.26], respectively. Thyroid dysfunction was identified in 19% of the participants, with hypothyroidism being the most common disorder (17%). Hyperthyroidism was observed in 2% of patients. Antithyroid antibodies were positive in 15.5% (n = 9) of participants, with TPOAb present in 6 patients (10.3%), TgAb in 3 patients (5.2%), and TRAb in 2 patients (3.4%). No statistically significant association was found between thyroid status and RA disease activity, functional impact, or serological status. Despite the lack of correlation, the high prevalence of thyroid dysfunction underscores the importance of regular thyroid screening to optimize management and prognosis in RA patients.

Indexed as

Arthritis, RheumatoidThyroid DiseasesThyroid GlandAdultAgedAutoantibodiesCase-Control StudiesFemaleHumansMiddle AgedPrevalenceThyroid Function TestsThyrotropinThyroxineAutoantibodiesThyrotropinThyroxineAnti-thyroid antibodyAutoimmunityRheumatoid arthritisThyroid dysfunctionThyroid hormone

Identifiers

PMID41044072
PMCPMC12494900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.